PCSK9 and rheumatoid arthritis: Nevertheless, whether there is a distinct pathogenic background or implication of disease-related inflammation or therapies affecting PCSK9 concentrations and acceleration of CVD in RA patients, needs to be examined in larger, prospective case-controls studies.